| 摘要 |
<p>Provided are TRAF6 and TAK1 which are new binding partners of PINK1, screening methods of a substance for preventing or treating neurodegenerative disorders using the same and a pharmaceutical compositions containing the substance. PINK1 stimulates the formation of a TRAF6-TAK1 complex, polyubiquitination and autophosphorylation of TAK1, and autodimerization and ubiquitylation of TRAF6. As a result, an IL-1 mediated-downstream signaling pathway is promoted, nuclear factor kappa (NF-kappaB) is activated and the productivity of inflammatory cytokines is increased. Therefore, the pharmaceutical composition containing a substance suppressing the expression of PINK1 and a substance suppressing the binding between PINK1 and TRAF6 or TAK1 as an active ingredient can be used for treating and preventing neurodegenerative disorders or symptoms.</p> |
